SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Condition:   Metastatic Renal Cell Carcinoma Interventions:   Drug: Ipilimumab;   Radiation: SBRT Sponsors:   Ontario Clinical Oncology Group (OCOG);   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials